Efficacy and Safety of Homeopathic Medicines in Diabetes, Pre-Diabetes, and Related Complications: Protocol for a Systematic Review and Meta-Analysis

Why It Matters

With nearly one billion people living with diabetes, robust evidence on complementary therapies like homeopathy could shape treatment guidelines, insurance coverage, and patient safety decisions.

Key Takeaways

• Diabetes affects ~1 billion adults worldwide, driving demand for alternatives
• Protocol targets RCTs/CCTs comparing homeopathy to placebo
• Outcomes include FBS, OGTT, HbA1c, NTSS‑6, disease progression
• GRADE and random‑effects meta‑analysis will assess evidence certainty
• Findings aim to inform clinicians, insurers, and regulatory bodies

Pulse Analysis

Diabetes and pre‑diabetes now affect close to a billion adults, imposing a heavy clinical and economic burden. As conventional therapies sometimes fall short of patient expectations, many turn to complementary approaches, with homeopathy emerging as a popular adjunct despite limited high‑quality data. Understanding the scale of this practice underscores the need for rigorous evaluation of its therapeutic value and safety profile.

The forthcoming systematic review follows best‑in‑class methodology, searching PubMed, Scopus, Cochrane CENTRAL, CAM‑Quest and grey‑literature sources such as ClinicalTrials.gov and WHO ICTRP. By including both randomized and controlled clinical trials, the investigators aim to capture the full spectrum of evidence. Advanced statistical techniques—random‑effects models with Hartung‑Knapp‑Sidik‑Jonkman correction—will be applied when two or more comparable studies report the same outcome, while the GRADE framework will grade confidence in the pooled estimates. This comprehensive approach addresses the current evidence gap and sets a benchmark for future complementary‑medicine meta‑analyses.

If the review demonstrates clinically meaningful benefits or highlights safety concerns, it could influence prescribing habits, insurance reimbursement policies, and regulatory oversight of homeopathic products. Conversely, a finding of negligible effect would reinforce reliance on established pharmacologic regimens. Either outcome will guide researchers toward targeted trials, help clinicians counsel patients more effectively, and inform health‑system decisions about integrating or restricting homeopathic interventions in diabetes care.